Description:Baricitinib phosphate salt is a pharmaceutical compound primarily used as a treatment for rheumatoid arthritis and has gained attention for its potential in treating COVID-19. It is a selective inhibitor of Janus kinase (JAK) enzymes, which play a crucial role in the signaling pathways of various cytokines involved in inflammatory processes. The compound is characterized by its ability to modulate immune responses, thereby reducing inflammation and joint damage in autoimmune conditions. Baricitinib phosphate salt is typically administered orally and is known for its relatively favorable pharmacokinetic profile, including good absorption and distribution in the body. Its chemical structure includes a phosphate group, which enhances its solubility and bioavailability. Safety and efficacy profiles have been established through clinical trials, although potential side effects may include increased risk of infections and changes in blood cell counts. Overall, Baricitinib phosphate salt represents a significant advancement in targeted therapies for inflammatory diseases.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![2-(3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-1-(Ethylsulfonyl)Azetidin-3-Yl)Acetonit…](https://static.cymitquimica.com/products/54/thumb/OR1026276.jpg)
